Eriko Yanagida

457 total citations
23 papers, 259 citations indexed

About

Eriko Yanagida is a scholar working on Immunology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Eriko Yanagida has authored 23 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 11 papers in Pathology and Forensic Medicine and 8 papers in Oncology. Recurrent topics in Eriko Yanagida's work include T-cell and Retrovirus Studies (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immune Cell Function and Interaction (4 papers). Eriko Yanagida is often cited by papers focused on T-cell and Retrovirus Studies (11 papers), Lymphoma Diagnosis and Treatment (10 papers) and Immune Cell Function and Interaction (4 papers). Eriko Yanagida collaborates with scholars based in Japan and Thailand. Eriko Yanagida's co-authors include Hiroaki Miyoshi, Koichi Ohshima, Kyohei Yamada, Keisuke Kawamoto, Takuya Furuta, Masao Seto, Mai Takeuchi, Takaharu Suzuki, Noriaki Yoshida and Kensaku Sato and has published in prestigious journals such as Human Pathology, Oncotarget and Modern Pathology.

In The Last Decade

Eriko Yanagida

22 papers receiving 257 citations

Peers

Eriko Yanagida

IMMUN

PFM

ONCOL

PHYSI

Amélie Trinquand France

M Kanda Japan

Aya Oshiro Japan

Erik Hameister Germany

H R Noel Germany

Yukihiro Tokumine Japan

W. Jung Germany

Sakiko Shimizu Japan

Bassam N. Smir United States

Julie C. Worrell United Kingdom

Amélie Trinquand France

Eriko Yanagida

119 ×0.9

IMMUN

137 ×1.0

PFM

121 ×1.0

ONCOL

30 ×0.9

PHYSI

102 ×3.2

Citations per year, relative to Eriko Yanagida Eriko Yanagida (= 1×) peers Amélie Trinquand

Countries citing papers authored by Eriko Yanagida

Since Specialization

Citations

This map shows the geographic impact of Eriko Yanagida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eriko Yanagida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eriko Yanagida more than expected).

Fields of papers citing papers by Eriko Yanagida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eriko Yanagida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eriko Yanagida. The network helps show where Eriko Yanagida may publish in the future.

Co-authorship network of co-authors of Eriko Yanagida

This figure shows the co-authorship network connecting the top 25 collaborators of Eriko Yanagida. A scholar is included among the top collaborators of Eriko Yanagida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eriko Yanagida. Eriko Yanagida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yanagida, Eriko, Akira Kubota, Hiroaki Miyoshi, et al.. (2023). The case of T-ALL presenting with NK phenotype after COVID-19 vaccination. Pathology - Research and Practice. 242. 154310–154310. 2 indexed citations

Yoshimura, Takuro, Hiroaki Miyoshi, Joji Shimono, et al.. (2022). CD37 expression in follicular lymphoma. Annals of Hematology. 101(5). 1067–1075. 7 indexed citations

Yanagida, Eriko, Hiroaki Miyoshi, Mai Takeuchi, et al.. (2022). Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma. Hematological Oncology. 40(4). 530–540. 3 indexed citations

Miyoshi, Hiroaki, Keisuke Kawamoto, Mai Takeuchi, et al.. (2021). Clinicopathological analysis of myeloid sarcoma with megakaryocytic differentiation. Pathology. 54(4). 442–448. 6 indexed citations

Arakawa, Fumiko, Hiroaki Miyoshi, Noriaki Yoshida, et al.. (2021). Expression of telomerase reverse transcriptase in peripheral T‐cell lymphoma. Cancer Medicine. 10(19). 6786–6794. 4 indexed citations

Yamada, Kyohei, Hiroaki Miyoshi, Noriaki Yoshida, et al.. (2020). Human T-cell lymphotropic virus HBZ and tax mRNA expression are associated with specific clinicopathological features in adult T-cell leukemia/lymphoma. Modern Pathology. 34(2). 314–326. 12 indexed citations

Yanagida, Eriko, Hiroaki Miyoshi, Mai Takeuchi, et al.. (2020). Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T‐cell leukemia/lymphoma. Hematological Oncology. 38(5). 680–688. 12 indexed citations

Takeuchi, Mai, Hiroaki Miyoshi, Kazutaka Nakashima, et al.. (2020). Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. Annals of Hematology. 99(5). 1093–1098. 13 indexed citations

Miyoshi, Hiroaki, Fumiko Arakawa, Joji Shimono, et al.. (2020). Clinicopathological features of in situ follicular neoplasm and relations with follicular lymphoma in Japan. Annals of Hematology. 99(2). 241–253.

10.

Suzuki, Takaharu, Hiroaki Miyoshi, Joji Shimono, et al.. (2020). Clinicopathological analysis of splenic red pulp low‐grade B‐cell lymphoma. Pathology International. 70(5). 280–286. 5 indexed citations

11.

Miyoshi, Hiroaki, Noriaki Yoshida, Kazutaka Nakashima, et al.. (2020). TACC3 expression as a prognostic factor in aggressive types of adult T‐cell leukemia/lymphoma patients. International Journal of Laboratory Hematology. 42(6). 842–848. 8 indexed citations

12.

Miyoshi, Hiroaki, Mamiko Sakata‐Yanagimoto, Joji Shimono, et al.. (2020). RHOA mutation in follicular T‐cell lymphoma: Clinicopathological analysis of 16 cases. Pathology International. 70(9). 653–660. 21 indexed citations

13.

Takeuchi, Mai, Hiroaki Miyoshi, Naoko Asano, et al.. (2019). Human leukocyte antigen class II expression is a good prognostic factor in adult T-cell leukemia/lymphoma. Haematologica. 104(8). 1626–1632. 25 indexed citations

14.

Suzuki, Takaharu, Hiroaki Miyoshi, Eriko Yanagida, et al.. (2019). CLINICOPATHOLOGICAL DIFFERENCES OF NODAL PTCL WITH TFH PHENOTYPE FROM AITL AND PTCL, NOS, AND DETECTION OF PROGNOSTIC MARKER OF NODAL PTCL WITH TFH PHENOTYPE. Hematological Oncology. 37(S2). 276–277. 2 indexed citations

15.

Yanagida, Eriko, Hiroaki Miyoshi, Keisuke Kawamoto, et al.. (2018). Clinicopathological analysis of immunohistochemical expression of retinoic acid–related orphan receptor-γt in peripheral T-cell lymphoma, not otherwise specified. Human Pathology. 79. 86–92. 2 indexed citations

16.

Masuda, Ken, Takaaki Tokito, Koichi Azuma, et al.. (2018). Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs. Thoracic Cancer. 9(6). 754–757. 3 indexed citations

17.

Kawamoto, Keisuke, Hiroaki Miyoshi, Eriko Yanagida, et al.. (2017). Comparison of clinicopathological characteristics between T‐cell prolymphocytic leukemia and peripheral T‐cell lymphoma, not otherwise specified. European Journal Of Haematology. 98(5). 459–466. 9 indexed citations

18.

Kawamoto, Keisuke, Hiroaki Miyoshi, Takaharu Suzuki, et al.. (2017). Frequent expression of CD30 in extranodal NK/T‐cell lymphoma: Potential therapeutic target for anti‐CD30 antibody‐based therapy. Hematological Oncology. 36(1). 166–173. 28 indexed citations

19.

Shimono, Joji, Hiroaki Miyoshi, Fumiko Arakawa, et al.. (2017). Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget. 8(58). 98723–98732. 20 indexed citations

20.

Kado, Tetsuji, et al.. (1998). [Psychiatric studies of chemotherapy and chemotherapy-induced nausea and vomiting of patients with lung or thymic cancer].. PubMed. 25(3). 403–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact